Cell lineage

Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024

Retrieved on: 
Tuesday, January 16, 2024
MSD, PRISM, Renal cell carcinoma, Hypoxia, Patient, HCC, Research, Neoplasm, Meta-analysis, Oxidative stress, Rescue coordination centre, RCC, Merck & Co., ASCO, Cell lineage, Everolimus, Society, Pembrolizumab, Headquarters, FGFR2, Deep, Cholangiocarcinoma, Drug discovery, Hepatocellular carcinoma, Cancer, Food, Proteostasis, CBP, Safety, Abstract, Food and Drug Administration, FDA, Inflammation, CREB-binding protein, Biomarker, LEAP, TKI, Merck, Differentiable function, Pharmaceutical industry

TOKYO, Jan 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually.

Key Points: 
  • TOKYO, Jan 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually.
  • First, the company will share findings in hepatocellular carcinoma (HCC) and cholangiocarcinoma during the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI24), which is taking place from January 18-20.
  • Tasurgratinib, for which a marketing authorization application was submitted in Japan in December 2023, is an orally available selective tyrosine kinase inhibitor of FGFR1-3.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains, with the aim of contributing to the cure of cancers.

Seattle Hub for Synthetic Biology launched by Allen Institute, Chan Zuckerberg Initiative, and the University of Washington will turn cells into recording devices to unlock secrets of disease

Retrieved on: 
Thursday, December 7, 2023
Synthetic, Research, Allen Institute, Gene, Pacific Northwest, Chan Zuckerberg Initiative, Autobiography, Disease, History, New institutional economics, Synthetic biology, CZI, Health, Personalized medicine, Genome, University, Cell lineage, Partnership, UW, Cell, Environment, Thought, Collaboration, Pharmaceutical industry, Vaccine, Management

SEATTLE, Dec. 7, 2023 /PRNewswire/ -- The Allen Institute, the Chan Zuckerberg Initiative (CZI), and the University of Washington (UW) today announced the launch of the Seattle Hub for Synthetic Biology: a landmark collaboration that will build new technologies to record the history of cells over time. These technologies will help researchers crack the code and understand not just end point measurements of cells and genes in health and disease but the dynamics of their trajectories over time. The Seattle Hub for Synthetic Biology brings together the best of large-scale science and philanthropy with proven academic power to develop, refine, and share this paradigm-shifting single-cell technology. Led by UW Medicine researchers Jay Shendure, M.D., Ph.D., Marion Pepper, Ph.D., Cole Trapnell, Ph.D., and Jesse Gray, Ph.D., the Seattle Hub for Synthetic Biology will build on technology pioneered at the Allen Discovery Center for Cell Lineage Tracing and UW Medicine's Brotman Baty Institute for Precision Medicine to reimagine living cells and genomes as devices for recording complex biological information over time.

Key Points: 
  • These technologies will help researchers crack the code and understand not just end point measurements of cells and genes in health and disease but the dynamics of their trajectories over time.
  • The Seattle Hub for Synthetic Biology brings together the best of large-scale science and philanthropy with proven academic power to develop, refine, and share this paradigm-shifting single-cell technology.
  • This new paradigm has the potential to revolutionize how scientists study the role of cells and genes in human health.
  • "Our shared values, paired with our complimentary perspectives and strengths, are a recipe for success, and I can't wait to see what this team will accomplish together."

Competition Yields New Approaches To Trace Development, Cell By Cell

Retrieved on: 
Wednesday, March 4, 2020
Biology, Philosophy of biology, Cell biology, Cell lineage, Lineage, Sage Bionetworks, Fate mapping, Evolutionary biology

SEATTLE, March 4, 2020 /PRNewswire/ --The Allen Institute and Sage Bionetworks today revealed the winning teams of the Allen Institute Cell Lineage Reconstruction DREAM Challenge, an open science competition for computational approaches to building accurate cell lineages in developmental biology.

Key Points: 
  • SEATTLE, March 4, 2020 /PRNewswire/ --The Allen Institute and Sage Bionetworks today revealed the winning teams of the Allen Institute Cell Lineage Reconstruction DREAM Challenge, an open science competition for computational approaches to building accurate cell lineages in developmental biology.
  • The experiments used in cell lineage tracing rely on molecular barcodes to reveal a developing creature's cellular pedigree.
  • "I am happy to see that participants to the challenge adapted approaches from evolutionary biology to the specific problems posed by cell lineage tracing.
  • Eleven international teams competed in the open science competition, which included three subchallenges that asked participants to reconstruct cell lineages from datasets of different sizes and types.